According to filings with the U.S. Securities and Exchange Commission, Actym Therapeutics is raising $27,539,376.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Christopher Thanos played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Actym Therapeutics
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies. Actym’s revolutionary therapeutic platform represents the next frontier in immuno-oncology, delivering multiplexed payloads directly to tumor-resident, antigen-presenting cells, after IV dosing. Actym has developed a novel, systemically administered therapeutic platform that can overcome the tumor immune microenvironment, which is hostile to T-cells. Our platform is based on a gene edited, immunologically cloaked microbe capable of enriching in solid tumors. Once there, multiplexed immuno-modulatory payloads are delivered directly to tumor-resident, antigen-presenting cells which allows for the multinodal targeting of the cancer immunity cycle.

To learn more about Actym Therapeutics, visit http://www.actymthera.com/

Contact:
Christopher Thanos, Chief Executive Officer
510-256-7167
https://www.linkedin.com/in/christopher-thanos-35972a37/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.